CardioLogical Receives Patent for Aortic Embolic Protection Devices to Prevent During TAVR

Technologies address the three biggest clinical needs to make transcatheter aortic valve replacement (TAVR) safer


April 12, 2013
Heart with Aorta

April 12, 2013 — CardioLogical Solutions, formed by the recent merger of Emboline and VasoStitch, has been issued an additional patent for its family of aortic embolic protection devices that are designed to prevent stroke and other ischemic complications.

The aortic embolic protection technologies of Emboline and the large-hole access and closure technologies of VasoStitch form the initial core of a suite of accessory devices offered by CardioLogical Solutions to address the clinical needs of emerging interventional cardiology procedures. Added to these is a novel approach to preventing contrast nephropathy during cardiovascular procedures.

“Our three platforms of procedural accessory devices address the three most pressing clinical needs in the rapidly growing evolution of transcatheter aortic valve replacement (TAVR) therapies: specifically, (1) a dire need for nonsurgical, large-hole (>12 Fr) access and closure technologies, (2) aortic embolic protection devices for prevention of stroke and other ischemic complications, and (3) prevention of contrast nephropathy,” said David W. J. Smith, CEO.

CardioLogical Solutions is currently in the advanced stages of raising a Series B preferred round to achieve CE mark for the initial Emboline and VasoStitch products and proof-of-concept for its contrast nephropathy technology.